Clinical Trials Directory

Trials / Completed

CompletedNCT04466839

Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients

Status
Completed
Phase
Study type
Observational
Enrollment
411 (actual)
Sponsor
University Hospital, Toulouse · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The consequences of COVID-19 in these already fragile patients should be evaluated. It will be important to appreciate the confinement consequences imposed on the patient on the course and impact of the disease. These consequences can be assessed by the end of confinement and 6 months after the latter is lifted.

Detailed description

Adaptation capacities are necessary to cope with the brutal and drastic changes imposed by the pandemic and its consequences. In Parkinson's disease, where there are routine situations with difficulties adjusting to newness, patients in the current situation may be particularly affected and present anxiety due to great difficulties in adaptation. The repercussions in terms of symptoms (motor and non-motor) of the disease could be very significant. In this population already widely exposed to anxio-depressive symptoms (depression being a common symptom of Parkinson's disease, affecting up to 30 to 40% of patients outside of crisis periods), we can expect a risk increased psychiatric decompensation. The psychiatric consequences could not be limited to the current period but also concern long-term patients, in particular if there is decompensation of other symptoms of the disease (motors, complications linked to treatment, etc.). The consequences of COVID-19 in these already fragile patients should be evaluated. It will be important to appreciate the confinement consequences imposed on the patient on the course and impact of the disease. These consequences can be assessed by the end of confinement and 6 months after the latter is lifted. This is an observational, French multicenter study, of an uncontrolled cohort of parkinsonian patients followed by doctors from Parkinson Expert Centers in hospitals.

Conditions

Interventions

TypeNameDescription
OTHERQuestionnaire and interviewThe questionnaires are Parkinson Disease Questionnaire-8 Items (PDQ-8) Visual Analog Scale (VAS) is visual analog scale visual numeric from 0 to 100, Neuropsychiatric Inventory-Questionnaire-Reduced (NPI-R) and Clinical Global Impression-Impairment (CGI-I).

Timeline

Start date
2020-07-02
Primary completion
2020-12-18
Completion
2020-12-18
First posted
2020-07-10
Last updated
2021-09-14

Locations

8 sites across 1 country: France

Source: ClinicalTrials.gov record NCT04466839. Inclusion in this directory is not an endorsement.